Chronic kidney disease. Anemia in chronic kidney disease
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion criteria included all male and female patients over the age of 18 years Not on hemodialysis or erythropoietin diagnosed as anemia with a baseline Hb of less than 13 g/dl in males and less than 12 g/dl in females With established chronic kidney disease with a GFR (glomerular filtration rate) of less than 60ml/min for more than 90 days assessed using the CKD-EPI equation and/or hyper albuminuria with urine albumin ? 30 mg in 24 hours or urine albumin to creatinine ratio (ACR) ? 30 mg/g.
Exclusion criteria
Exclusion criteria: Exclusion criteria included patients on dialysis, erythropoietin or use of erythropoietin stimulating agents (ESAs) in the last 3 months Patients with advanced liver, cardiac or ESKD (end-stage kidney disease) Drug allergies to iron and its supplemental form during therapy or previous known history Unwilling to be included in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum iron levels. Timepoint: 4 weeks after starting therapy. Method of measurement: Blood levels.;Serum Hb. Timepoint: 4 weeks after therapy. Method of measurement: Blood levels.;Serum Ferritin levels. Timepoint: 4 weeks after therapy. Method of measurement: Blood levels.;Serum transferrin and TIBC levels. Timepoint: 4 weeks after therapy. Method of measurement: Blood levels. | — |
Secondary
| Measure | Time frame |
|---|---|
| Constipation and diarrhea. Timepoint: During 4 weeks of therapy. Method of measurement: Patient history.;Allergy to iron supplementation. Timepoint: During 4 weeks of therapy. Method of measurement: Patient assessment weekly during treatment. | — |
Countries
Pakistan
Contacts
Pak Emirates Military Hospital Rawalpindi